Tuesday, October 15, 2013
Louisville's New Slugger, GlobeImmune, Hits a Homer with Tarmogen for Hepatitis B
Louisville-based GlobeImmune Inc. received a milestone payment from Gilead Sciences Inc. as a result of the biotechnology firms' 2011 collaboration agreement for the development and commercialization of Tarmogen products, officials announced Tuesday.
Triggering the payment was the initiation of a Phase 2 clinical trial for the investigation of the GS-4774 Tarmogen in patients with chronic hepatitis B virus. GlobeImmune and Gilead's 2011 partnership centers on the development and commercialization of Tarmogens for use in conjunction with Viread — a Gilead drug — and other oral therapies for the treatment of chronic HBV.